BC
RIGL icon

Broadfin Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Broadfin Capital’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-312,528
Closed -$9.47M – 84
2015
Q4 		$9.47M Sell
312,528
-200,000
-39% -$6.06M 0.58% 48
2015
Q3 		$12.7M Sell
512,528
-75,147
-13% -$2.24M 0.7% 32
2015
Q2 		$18.9M Sell
587,675
-236,958
-29% -$9.05M 1.01% 23
2015
Q1 		$29.4M Sell
824,633
-25,542
-3% -$700K 2.29% 10
2014
Q4 		$19.3M Buy
850,175
+250,373
+42% +$5.06M 1.68% 18
2014
Q3 		$11.6M Buy
599,802
+40,000
+7% +$1.13M 1.22% 24
2014
Q2 		$20.3M Buy
559,802
+14,290
+3% +$486K 1.98% 17
2014
Q1 		$21.2M Buy
545,512
+50,000
+10% +$1.78M 2.05% 14
2013
Q4 		$14.1M Buy
495,512
+138,930
+39% +$4.08M 1.86% 21
2013
Q3 		$12.8M Buy
356,582
+51,582
+17% +$1.88M 2.27% 17
2013
Q2 		$10.2M Buy
+305,000
New +$13.8M 1.99% 17

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Broadfin Capital's RIGL Position: Q1 2016 in Review

Broadfin Capital sold out of Rigel Pharmaceuticals (RIGL) in Q1 2016, closing a stake of 312,528 shares — an estimated $9.47M sold.

Broadfin Capital first reported a position in RIGL in Q2 2013 and held it in 11 quarters. The position peaked at $29.4M in Q1 2015. 120 funds tracked by Wall St. Rank hold RIGL as of Q1 2016.

  • Broadfin Capital reported no remaining Rigel Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Broadfin Capital sold 312,528 Rigel Pharmaceuticals shares in Q1 2016, an estimated $9.47M.
  • Broadfin Capital first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Broadfin Capital's Rigel Pharmaceuticals position peaked at $29.4M in Q1 2015.
  • 120 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.